Journal
CELLULAR & MOLECULAR IMMUNOLOGY
Volume 11, Issue 1, Pages 14-16Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/cmi.2013.60
Keywords
immune tolerance; immunogenicity; induced pluripotent stem cells; minor antigen; transplantation
Categories
Funding
- NSFC [81172828, 81373166]
Ask authors/readers for more resources
With their ability to undergo unlimited self-renewal in culture and to differentiate into all cell types in the body, human embryonic stem cells (hESCs) hold great potential for the treatment of currently incurable diseases. Two hESC-based cell therapies for spinal cord injury and macular degeneration have been advanced into human clinical trials. Despite this rapid progress, one key challenge of hESC-based cell therapy is the allogeneic immune rejection of hESC-derived cells by recipients. This problem could be mitigated by a recent breakthrough in the technology of induced pluripotent stem cells (iPSCs) by nuclear reprogramming of patient-specific somatic cells with defined factors, which could become a renewable source of autologous cells for cell therapy. However, recent studies revealing the abnormal epigenetics, genomic stability and immunogenicity of iPSCs have raised safety concerns over iPSC-based therapy. Recent findings related to the immunogenicity of iPSC derivatives will be summarized in this review.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available